Context Therapeutics reports interim phase 1 trial results for CTIM-76

June 15, 2026 6:30 AM

Context Therapeutics Inc. (NASDAQ: CNTX) announced interim results from its ongoing Phase 1 clinical trial of CTIM-76, a bispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found